Aldeyra Therapeutics (ALDX) Net Equity Issued and Repurchased (2013 - 2021)

Aldeyra Therapeutics (ALDX) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $119.8 million in Q2 2021.

• Quarterly Net Equity Issued and Repurchased rose 868.1% year-over-year to $119.8 million in Q2 2021, while the trailing twelve-month figure through Mar 2022 was $119.8 million (down 12.9% YoY) and the FY2021 annual result came in at $189.8 million, up 366.18% from the prior year.
• Net Equity Issued and Repurchased rose to $119.8 million in Q2 2021, from $100.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $119.8 million in Q2 2021 to a low of -$86643.0 in Q2 2019.
• A 5-year average of $22.8 million and a median of $7.2 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2018 — Net Equity Issued and Repurchased soared 1504932.73% — and 2019, when it sank 100.96%.
• Tracing ALDX's Net Equity Issued and Repurchased over 5 years: stood at -$4495.0 in 2017, then soared by 1504932.73% to $67.6 million in 2018, then slumped by 89.4% to $7.2 million in 2019, then tumbled by 100.0% to $1.0 in 2020, then jumped by 11979999900.0% to $119.8 million in 2021.
• The last three Net Equity Issued and Repurchased figures came in at $119.8 million (Q2 2021), $100.0 million (Q1 2021), and $1.0 (Q4 2020), per Business Quant data.